(Q28192856)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16246214%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

review article

1 reference

title

Diagnosis and management of the metabolic syndrome in obesity (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16246214%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

0 references

1 reference

Evangelos N Liberopoulos

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16246214%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Moses Elisaf

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16246214%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

author name string

Mikhailidis DP

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16246214%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

language of work or name

English

0 references

publication date

1 November 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16246214%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16246214%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

volume

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16246214%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16246214%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

page(s)

283-296

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16246214%20AND%20SRC:MED&resulttype=core&format=json

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

8 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1111/J.1467-789X.2005.00221.X

Treatment of metabolic syndrome

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1467-789X.2005.00221.X

Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1467-789X.2005.00221.X

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1467-789X.2005.00221.X

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1467-789X.2005.00221.X

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1467-789X.2005.00221.X

Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1467-789X.2005.00221.X

The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [ISRCTN64783481]

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1467-789X.2005.00221.X

Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1467-789X.2005.00221.X

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1467-789X.2005.00221.X

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1467-789X.2005.00221.X

Management of metabolic syndrome: aspirin

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1467-789X.2005.00221.X

Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition

21 April 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

21 April 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

21 April 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 April 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

21 April 2017

The metabolic syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

The metabolic syndrome: requiescat in pace

21 April 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

The obesity epidemic, metabolic syndrome and future prevention strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

Characteristics of US adults with the metabolic syndrome and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

Impact of lifestyle habits on the prevalence of the metabolic syndrome among Greek adults from the ATTICA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

The prevalence of the metabolic syndrome in Greece: the MetS-Greece Multicentre Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

Metabolic syndrome and coronary heart disease in South Asians, African-Caribbeans and white Europeans: a UK population-based cross-sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

Prevalence of coronary heart disease and carotid arterial thickening in patients with the metabolic syndrome (The ARIC Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

Prevalence of atherosclerotic vascular disease among subjects with the metabolic syndrome with or without diabetes mellitus: the METS-GREECE Multicentre Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

Risk factors for first-ever acute ischemic non-embolic stroke in elderly individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

The prevalence of the metabolic syndrome using the National Cholesterol Educational Program and International Diabetes Federation definitions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

Prevention and treatment of the metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

Epidemiology and treatment of the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

Metabolic syndrome: the new cardiovascular target

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

Therapeutic approaches in the prevention of cardiovascular disease in metabolic syndrome and in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

Focus on lifestyle change and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

Lifestyle behaviors associated with lower risk of having the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

Effects of weight loss in overweight/obese individuals and long-term lipid outcomes--a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

Intentional weight loss and death in overweight and obese U.S. adults 35 years of age and older

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

A review of the metabolic effects of sibutramine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

The ORLIstat and CArdiovascular risk profile in patients with metabolic syndrome and type 2 DIAbetes (ORLICARDIA) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

Emerging aspects of pharmacotherapy for obesity and metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

Rimonabant--a selective CB1 antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Ph

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

American Diabetes Association position statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

Metabolic syndrome: dietary interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

Nutritional aspects in the causation and management of the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

Adherence to a Mediterranean diet and survival in a Greek population

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

Effect of alcohol consumption on diabetes mellitus: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

Incidence of type 2 diabetes in the randomized multiple risk factor intervention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

Emerging therapeutic strategies for the management of dyslipidemia in patients with the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

Cardiovascular disease with diabetes or the metabolic syndrome: should statins or fibrates be first line lipid therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

Management of metabolic syndrome: statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

A review of the lipid-related effects of fluvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

Effects of fibrates on serum metabolic parameters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

Combined treatment with fibrates and small doses of atorvastatin in patients with mixed hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

Effects of micronized fenofibrate on insulin resistance in patients with metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

The effects of the addition of micronised fenofibrate on uric acid metabolism in patients receiving indapamide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

Omega-3 fatty acids: molecular approaches to optimal biological outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

The metabolic syndrome: pathophysiology, clinical relevance, and use of niacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

Glitazones and the management of insulin resistance: what they do and how might they be used

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2005.00221.X